Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Inclusion Criteria: * Patients aged more than 18 years. * Refractory or relapsed peripheral T-cell NHL (PTCL) * Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy * ECOG score less than 2 * No major organ dysfunction unrelated to lymphoma. Exclusion Criteria: * Pregnant or breast feeding women * ECOG score \> 2 * Estimate survival time \< 3 months * Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy * Creatinine clearance \< 10 ml/min or severe hepatic dysfunction not related to lymphoma. * Previous chemotherapy/immunotherapy within 3 weeks before study entry * Known seropositive for or active viral infection HIV, EBV, HCV * CNS lymphoma * T-cell Leukemia lymphoma associated with HTLV1 * Sezary syndrome